SCHEMBL3708602

SCHEMBL3708602

CC(C)(P)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.50
ALDH1A1 P00352 3/20 0.46
TAAR1 Q96RJ0 1/20 0.46
ALOX15 P16050 1/20 0.46
ESR1 P03372 2/20 0.44
ESR2 Q92731 2/20 0.44
CYP3A4 P08684 1/20 0.44
KCNN4 O15554 4/20 0.43
TSHR P16473 2/20 0.43
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
CYP2C19 P33261 1/20 0.41
HIF1A Q16665 1/20 0.41
CYP2B6 P20813 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL8601711 0.97 MAPK1 (0.48) MAPK1ALDH1A1TAAR1ALOX15ESR1
SCHEMBL4449679 0.81 ESR1 (0.46) MAPK1ALDH1A1TAAR1ALOX15ESR1
SCHEMBL842144 0.81 MAPK1 (0.50) MAPK1ALDH1A1TAAR1ALOX15ESR1
SCHEMBL2012032 0.77 MAPK1 (0.46) MAPK1ALDH1A1TAAR1ALOX15ESR1
SCHEMBL662183 0.77 MAPK1 (0.46) MAPK1ALDH1A1TAAR1ALOX15ESR1
SCHEMBL3264960 0.77 MAPK1 (0.46) MAPK1ALDH1A1TAAR1ALOX15ESR1
Hydrochloric Acid SCHEMBL8007212 0.77 MAPK1 (0.46) MAPK1ALDH1A1TAAR1ALOX15ESR1
SCHEMBL28902292 0.75 MAPK1 (0.44) MAPK1ALDH1A1TAAR1ALOX15ESR1
SCHEMBL16859261 0.75 MAPK1 (0.44) MAPK1ALDH1A1TAAR1ALOX15ESR1
SCHEMBL909383 0.75 MAPK1 (0.44) MAPK1ALDH1A1TAAR1ALOX15ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435181-B2 Formulations capable of reacting with or removal of molecular oxygen LI SHENSHEN (US) 2025-10-07 US disclosed
CN-119136667-A Ready-to-use plant treatment agent applicators, containers, and products UPL有限责任公司 2024-12-13 CN disclosed
WO-2023181905-A1 LAMINATE MANUFACTURING METHOD 日本発條株式会社 2023-09-28 WO disclosed
US-20230271953-A1 Novel compounds for treatment of diseases related to DUX4 expression Facio Intellectual Property B.V. (NL) 2023-08-31 US disclosed
CN-112912364-B Effect of catalyst concentration and solid activator on nickel-mediated coupling of olefins/carbon dioxide with acrylates 切弗朗菲利浦化学公司 2023-07-07 CN disclosed
US-20220235174-A1 Formulations capable of reacting with or removal of molecular oxygen LI ZHENZHEN (CN) 2022-07-28 US disclosed
CN-109071520-B Microbicidal oxadiazole derivatives 先正达参股股份有限公司 2022-06-14 CN disclosed
CN-114390888-A Plant supplement delivery assembly, plant supplement delivery assembly insert and method for delivering plant supplement 巴特尔纪念研究院 2022-04-22 CN disclosed
WO-2022033893-A1 HERBICIDAL COMPOSITIONS SYNGENTA CROP PROTECTION AG (CH) 2022-02-17 WO disclosed
US-20210403702-A1 THERMOSETTING EPOXY RESIN COMPOSITION, CIRCUT BOARD LAMINATE, METAL-BASED CIRCUT BOARD, AND POWER MODULE NHK SPRING CO., LTD. (JP) 2021-12-30 US disclosed
US-7256314-B2 Method for generating secondary phosphines BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2007-08-14 US disclosed
US-20070149820-A1 METHOD FOR GENERATING SECONDARY PHOSPHINES BUSACCA CARL A 2007-06-28 US disclosed
EP-1732876-A1 PREPARATION OF LEVULINIC ACID ESTERS FROM ALPHA-ANGELICA LACTONE AND ALCOHOLS E.I.Du pont de nemours and company (US) 2006-12-20 EP disclosed
WO-2005097724-A1 PREPARATION OF LEVULINIC ACID ESTERS FROM ALPHA-ANGELICA LACTONE AND ALCOHOLS E.I. DUPONT DE NEMOURS AND COMPANY (US) 2005-10-20 WO disclosed
US-20050210738-A1 Preparation of levulinic acid esters from alpha-angelica lactone and alcohols E. I. DU PONT DE NEMOURS AND COMPANY 2005-09-29 US disclosed
US-20050203314-A1 Method for generating secondary phosphines BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-09-15 US disclosed
WO-2005068479-A1 A METHOD FOR GENERATING SECONDARY PHOSPHINES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-07-28 WO disclosed
EP-0536036-B1 Cardioprotective tocopherol analogs MERRELL PHARMA INC (US) 1998-02-25 EP disclosed
EP-0536036-A1 Cardioprotective tocopherol analogs MERRELL PHARMACEUTICALS INC. (US) 1993-04-07 EP disclosed
EP-0535283-A1 Cardioprotective tocopherol analogs MERRELL DOW PHARMACEUTICALS INC. (US) 1993-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149820-A1 METHOD FOR GENERATING SECONDARY PHOSPHINES HRH3, DBH, HDHD5 MAPK1 4192/4885ALDH1A1 3016/4885TAAR1 543/4885
US-20050210738-A1 Preparation of levulinic acid esters from alpha-angelica lactone and alcohols ADH1C, ADH1A, ADH5 MAPK1 3617/4885ALDH1A1 6/4885TAAR1 2570/4885
US-20230271953-A1 Novel compounds for treatment of diseases related to DUX4 expression UTRN, ZFX, CBX6 MAPK1 4043/4885ALDH1A1 2505/4885TAAR1 4368/4885
US-20050203314-A1 Method for generating secondary phosphines HRH3, DBH, HDHD5 MAPK1 4192/4885ALDH1A1 3016/4885TAAR1 543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.